Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
about
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.B7-H3 role in the immune landscape of cancer.Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.Reduced sB7-H3 Expression in the Peripheral Blood of Systemic Lupus Erythematosus Patients.212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models.Next generation of immune checkpoint therapy in cancer: new developments and challenges.Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures Suggests Potential Therapeutic Targets and Prognosis Prediction Approaches in Kidney Cancer.Immunological-based approaches for cancer therapyLarge-scale analysis reveals the specific clinical and immune features of B7-H3 in gliomaClinical correlation of B7-H3 and B3GALT4 with the prognosis of colorectal cancerCAR T Cell Therapy for Neuroblastoma
P2860
Q34548319-CD0F9A63-144E-4A69-B7F5-1A7A3D24AA1AQ38666253-407BCD97-3995-4C8C-AB48-1B8E52F7823CQ38670099-16541CBE-B3F1-4162-B0BF-168E4C1A3CB7Q39160982-0BC4BB60-8284-4F57-BBB4-43D8625BB73FQ39427326-B8BA1359-B45D-46DF-BFBE-B11E79DB2CEBQ39446788-22E19E68-DEA1-4169-A72C-3FFC7532059EQ41022992-01A71067-620B-46EC-87F8-F1647FBF5BB0Q48131888-EF42BDD5-F65E-4A40-973A-DD4B3328E001Q49176886-7CA2FF78-1689-4EF4-B38E-3D3E7AED6ECEQ50138482-04CE5ED1-DA2A-4F21-8906-264BDDC9CD94Q52653710-CF98F8C3-9B1E-4043-A30B-6758C1AB9380Q52683991-B0E07F4F-DF87-4AA7-A111-90476D336042Q52720460-A63FA032-E94D-4E0A-B1D8-DD893F4C9B0BQ55024837-707F1E67-4856-4B54-B830-EF03935AC24CQ57168423-4E80FB7A-F8B7-4B2F-BB71-97C0C51FB21FQ58129683-930136BF-DA6A-4F0B-9DDE-49DE5C9192B3Q58731771-33594E15-AAA6-46C9-B60C-F12EC7E90821Q59127901-75B0F21B-E7D5-433A-AFAE-6B81FD648E49
P2860
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
@en
type
label
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
@en
prefLabel
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
@en
P2093
P2860
P1476
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
@en
P2093
Elodie Picarda
Kim C Ohaegbulam
Xingxing Zang
P2860
P304
P356
10.1158/1078-0432.CCR-15-2428
P407
P577
2016-05-20T00:00:00Z